Interleukin 19, Recombinant, Human (IL-19, Melanoma Differentiation Associated like Protein)

Interleukin-19 (IL-19) is a novel cytokine that was initially identified during a sequence data base search aimed at finding potential Interleukin-10 homologs. Interleukin-19 shares 21% amino acid identity with IL-10. The exon/intron structure of IL-19 is similar to that of the human IL-10 gene, comprising five exons and four introns within the coding region of the IL-19 cDNA. IL-19 shares a receptor complex with IL-20, indicating that the biological activities of these two cytokines overlap and that both may play an important role in regulating development and proper functioning of the skin. Unlike IL-10, which forms an intercalated dimer, the molecule of IL-19 is a monomer made of seven amphipathic helices, A-G, creating a unique helical bundle.\n\nDescription: \nRecombinant Human IL-19 produced in E.Coli is a single, non-glycosylated polypeptide chain containing 155 amino acids and having a molecular mass of 17913 Dalton. Recombinant Human Interleukin-19 is purified by proprietary chromatographic techniques.\n\nAmino Acid Sequence: \nThe sequence of the first five N-terminal amino acids was determined and was found to be Met-Leu-Arg-Arg-Cys.\n\nDimers and Aggregates: \nLess than 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity: \nRecombinant Human Interleukin-19 is fully biologically active when compared to standard. The activity is determined by it's ability to activate STAT following receptor-ligand interaction.\n\nEndotoxin: \n(same/less than) 0.1ng/ug (IEU/ug) of human IL-19.\n\nProtein Content: \nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280nm. \n2. Analysis by RP-HPLC, using a standard solution of IL-19 as a Reference Standard.\n\nSolubility: \nIt is recommended to reconstitute the lyophilized Interleukin-19 in sterile 18MOmega-cm H2O not less than 100microg/ml, which can then be further diluted to other aqueous solutions.\n\nStability: \nLyophilized Interleukin-19 although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution Recombinant Human IL-19 should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8441-01A

Size

2ug

Form

Supplied as a lyophilized powder in 10mM sodium citrate, pH 3.0.

Purity

(same/more than) 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Induction of interleukin-19 and interleukin-22 after cardiac surgery with cardiopulmonary bypass.\n\nAnn Thorac Surg 2006 Jun;81(6):2196-201\n\n2. Promoter analysis of interleukin 19.\n\nBiochem Biophys Res Commun 2006 Jun 9;344(3):713-20\n\n3. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis.\n\nBr J Dermatol 2005 Nov;153(5):911-8\n\n4. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis.\n\nBr J Dermatol 2005 Sep;153(3):591-5\n\n5. Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis.\n\nGenes Immun 2004 Dec;5(8):662-7\n\n6. Molecular modeling of the interleukin-19 receptor complex. Novel aspects of receptor recognition in the interleukin-10 cytokine family.\n\nJ Mol Model (Online) 2004 Aug;10(4):290-6